LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.
Jean-Pascal H. Machiels
Consultant or Advisory Role - Boehringer Ingelheim
Lisa F. Licitra
No relevant relationships to disclose
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim (U)
Makoto Tahara
Consultant or Advisory Role - Merck Serono
Research Funding - Eisai; Yakult Honsha
Liz Svensson
Employment or Leadership Position - Boehringer Ingelheim
Xiuyu Julie Cong
Employment or Leadership Position - Boehringer Ingelheim
Eva Ehrnrooth
Employment or Leadership Position - Boehringer Ingelheim
Ezra E. W. Cohen
Consultant or Advisory Role - Boehringer Ingelheim (U)